Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 5:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 564 matching trials from the live ClinicalTrials.gov search.
Conditions
Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Leptomeninges
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Radiation Therapy, Resection, Trotabresib, Vinorelbine
Procedure · Radiation · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
Interventions
Magnetic Resonance Imaging using 7 Tesla MRI
Diagnostic Test
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Terminated Phase 1 Interventional

Study of Immunotoxin, MR1-1

NCT01009866
Conditions
Supratentorial Malignant Brain Tumor
Interventions
MR1-1
Biological
Lead sponsor
Darell D. Bigner, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Active, not recruiting Early Phase 1 Interventional Accepts healthy volunteers

Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma

NCT05045027
Conditions
Glioma, Malignant Glioma, Recurrent Glioma, Recurrent Malignant Glioma
Interventions
Biospecimen Collection, Diagnostic Imaging, Magnetic Resonance Imaging
Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Malignant Glioma, Recurrent Brain Neoplasm
Interventions
Biopsy, Computed Tomography, Diffusion Weighted Imaging, Fluorine F 18 Fluorodopa, Laboratory Biomarker Analysis, Perfusion Magnetic Resonance Imaging, Positron Emission Tomography, Therapeutic Conventional Surgery
Procedure · Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
7 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Brain Tumors, Osteoporosis, Central Nervous System(CNS)Malignancies
Interventions
IV Zometa
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Brain and Central Nervous System Tumors, Neuroblastoma, Retinoblastoma, Sarcoma
Interventions
filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, leucovorin calcium, methotrexate, temozolomide, thiotepa, vincristine sulfate, autologous bone marrow transplantation, peripheral blood stem cell transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
NYU Langone Health
Other
Eligibility
Up to 10 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
17
States / cities
Honolulu, Hawaii • Scarborough, Maine • Grand Rapids, Michigan + 11 more
Conditions
Brain Tumors
Interventions
5-aminolevulinic acid
Drug
Lead sponsor
David W. Roberts
Other
Eligibility
21 Years and older
Enrollment
540 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Lebanon, New Hampshire
Recruiting Not applicable Interventional

FearLess in NeuroOncology

NCT06989086
Conditions
Primary Malignant Brain Tumor, Glioblastoma (GBM), Astrocytoma, Oligodendroglioma, Caregiver
Interventions
Fearless in Neuro-Oncology
Behavioral
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Richmond, Virginia
Conditions
Malignant Brain Neoplasm, Recurrent Malignant Brain Neoplasm, Refractory Malignant Brain Neoplasm
Interventions
Cyclophosphamide, Fludarabine, IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes
Drug · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
4 Years to 25 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
3
States / cities
Duarte, California • Los Angeles, California • Ann Arbor, Michigan
Conditions
Glioblastoma, Gliosarcoma
Interventions
Imatinib Mesylate & Hydroxyurea
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Malignant Glioma of Brain, Glioblastoma
Interventions
Palliative regimen consisting of LITT
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Malignant Glioma, Glioblastoma, Brain Cancer, Gliosarcoma
Interventions
Epidermal growth factor receptor(EGFRv)III Chimeric antigen receptor (CAR) transduced PBL, Aldesleukin, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm
Interventions
Dexamethasone, Resection, Stereotactic Radiosurgery
Drug · Procedure · Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
Extensive Stage Lung Small Cell Carcinoma, Malignant Solid Neoplasm, Metastatic Malignant Neoplasm in the Brain
Interventions
Atezolizumab, Carboplatin, Entinostat, Etoposide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
5
States / cities
New York, New York • Pittsburgh, Pennsylvania • Salt Lake City, Utah + 2 more
Conditions
Malignant Primary Brain Tumors, Brain Metastases, Adult
Interventions
Pritumumab
Biological
Lead sponsor
Nascent Biotech
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Newport Beach, California • San Diego, California
Conditions
Recurrent Childhood Medulloblastoma, Recurrent Ependymoma, Recurrent Medulloblastoma
Interventions
Laboratory Biomarker Analysis, Natural Killer Cell Therapy
Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Houston, Texas
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain
Interventions
Copper Cu 64-DOTA-Trastuzumab, Magnetic Resonance Imaging, Positron Emission Tomography, Trastuzumab, Trastuzumab Deruxtecan
Other · Procedure · Device + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Duarte, California
Conditions
Cognitive Side Effects of Cancer Therapy, Malignant Ovarian Epithelial Tumor, Ovarian Brenner Tumor, Ovarian Carcinosarcoma, Ovarian Choriocarcinoma, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Dysgerminoma, Ovarian Embryonal Carcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mixed Germ Cell Tumor, Ovarian Mucinous Cystadenocarcinoma, Ovarian Polyembryoma, Ovarian Sarcoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Teratoma, Ovarian Yolk Sac Tumor, Stage I Ovarian Cancer, Stage IA Fallopian Tube Cancer, Stage IA Ovarian Cancer, Stage IA Ovarian Germ Cell Tumor, Stage IB Fallopian Tube Cancer, Stage IB Ovarian Cancer, Stage IB Ovarian Germ Cell Tumor, Stage IC Fallopian Tube Cancer, Stage IC Ovarian Cancer, Stage IC Ovarian Germ Cell Tumor, Stage II Ovarian Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIA Ovarian Germ Cell Tumor, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIB Ovarian Germ Cell Tumor, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIC Ovarian Germ Cell Tumor, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Ovarian Germ Cell Tumor, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Ovarian Germ Cell Tumor, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Ovarian Germ Cell Tumor, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Primary Peritoneal Cancer, Undifferentiated Ovarian Carcinoma
Interventions
Cognitive Assessment, Quality-of-Life Assessment
Procedure · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
182
States / cities
Tucson, Arizona • Little Rock, Arkansas • Burbank, California + 129 more
Conditions
Constitutional Mismatch Repair Deficiency Syndrome, Lynch Syndrome, Malignant Glioma, Recurrent Brain Neoplasm, Recurrent Childhood Ependymoma, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma, Refractory Brain Neoplasm, Refractory Diffuse Intrinsic Pontine Glioma, Refractory Ependymoma, Refractory Medulloblastoma
Interventions
Biospecimen Collection, Conventional Magnetic Resonance Imaging, Diffusion Tensor Imaging, Diffusion Weighted Imaging, Dynamic Contrast-enhanced MR Perfusion, Dynamic Susceptibility Contrast-Perfusion-Weighted Imaging, Magnetic Resonance Spectroscopic Imaging, Pembrolizumab
Procedure · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 30 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2027
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 8 more
Conditions
Central Nervous System Embryonal Neoplasm, Embryonal Tumor With Multilayered Rosettes, C19MC-Altered, Germ Cell Tumor, Medulloblastoma, Medulloepithelioma, Primitive Neuroectodermal Tumor, Recurrent Childhood Central Nervous System Embryonal Neoplasm, Recurrent Malignant Germ Cell Tumor, Recurrent Medulloblastoma, Recurrent Primitive Neuroectodermal Tumor
Interventions
Carboplatin, Mannitol, Melphalan, Quality-of-Life Assessment, Questionnaire Administration, Sodium Thiosulfate
Drug · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 45 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
2
States / cities
Minneapolis, Minnesota • Portland, Oregon
Conditions
Melanoma, Glioma, Thyroid Cancer, Non-Small Cell Lung Cancer, Malignant Neoplasms, Brain Neoplasms, Advanced or Metastatic Solid Tumors, HGG, LGG, Low Grade Glioma, High Grade Glioma, Differentiated Thyroid Cancer, NSCLC (Non-small Cell Lung Cancer)
Interventions
PF-07799544, PF-07799933
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
44
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Rogers, Arkansas + 22 more
Conditions
Primary Malignant Brain Tumors
Interventions
CAU+ (Enhanced Care as Usual), Beating the Blues, SmartCare
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
21 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Brain Neoplasm, Metastatic Malignant Neoplasm in the Brain, Recurrent Brain Neoplasm
Interventions
Direct Electrocortical Stimulation, Electrocorticography
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
1
States / cities
Houston, Texas